Resources
- BNET Author Biography
Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years. He is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. He has also won the Neal award for business journalism, an S.P.J. award for investigative journalism, and the N.J. Press...- more about Jim Edwards »
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Nestle Exec Had "Tirade" Over News America's Pricing; Mixson Says He Always Does That
- News America Marketing president Chris Mixson testified in a Michigan state court that Nestle director of promotional services Glenn Barry flew into a "tirade" over the agency's alleged "punitive" pricing. The testimony came in a trial where rival agency Valassis is hoping to prove that News America raised prices...
- Blog posts 2009-07-04
- Source: Sanofi to Ax 60 Jobs at Great Valley, Pa., Site
- A source tells BNET that Sanofi-Aventis is to lay off 60-plus staff at its Great Valley, Pa., site. The move came after the company's restructuring statement said the ax would fall mainly in France. by Jim Edwards
- Blog posts 2009-07-04
- In Elan-J&J Deal, Many Unanswered Questions (Wyeth Being One)
- Johnson & Johnson's investment of $1 billion for an 18.34 percent stake in Elan raises more questions than answers. It promises to bring Elan's Alzheimer's candidate, bapineuzumab, to market but details of exactly how that will happen have yet to be revealed. by Jim Edwards
- Blog posts 2009-07-04
- Subway Will Use Phelps in Ads Despite Bong Photo
- Sandwich chain Subway will feature swimmer Michael Phelps in TV advertising from MMB, Ad Age reported. The news is significant because it answers a question raised by BNET in February over whether Subway's consumers and management were adult enough to handle the news that Phelps was photographed smoking a marijuana...
- Blog posts 2009-07-04
- Citi Cuts WPP to "Sell"; Sorrell Defends "Suicide Pact" on Pay; Attacks Obama on Taxes
- As WPP stock fell 7 percent Friday as Citigroup rated it a "sell," on the basis that 2009 may not be the bottom of the recession in advertising. The news dovetails BNET's theory of June 20 that WPP's Q2 results won't be pretty. WPP chief Martin Sorrell reiterated as much...
- Blog posts 2009-07-04
- Why Levaquin Mass Tort Ruling May Favor J&J
- New Jersey Supreme Court's consolidation of cases regarding the antibiotic Levaquin into a mass tort in Atlantic County Superior Court at first looks like bad news for Johnson & Johnson. After all, Judge Carol Higbee's courthouse-by-the-casinos is where Merck was eventually forced into a $4.85 billion settlement of its Vioxx...
- Blog posts 2009-07-04
- Weight-Loss Drugs -- Big Pharma’s Elusive El Dorado
- With America’s obesity problem getting worse by the day, there's plenty of money to be made fighting fat with new drugs. So why do weight-loss pills keep going down in flames? by Jim Edwards
- Blog posts 2008-07-30
- What’s Inside That FTC Report on Junk Food Marketing?
- The FTC detailed this week how much money is spent marketing junk food to kids. Most stories, like this one in the New York Times, went with the headline number: $1.6 billion. But the full report is more than 100 pages long, and filled with scary hidden...
- Blog posts 2008-07-31
- FDA Probes Shine Harsh Light on Pharma Biz
- It must be awful to work at the FDA right now. There you are, sitting in your cubicle, trying to make sure the pharmaceutical industry cures more people than it kills. But every five minutes some investigator from the Government Accountability Office calls you into the conference room for a...
- Blog posts 2008-07-31
- Should We Be Surprised That Schering-Plough Execs Are "Surprised" By Sugammadex Rejection?
- Yet another setback for Schering-Plough seems to have taken top management by surprise. Schering’s shares slid nearly four percent by midafternoon on the news that its sugammadex anesthesia-recovery drug would not be approved by the FDA. In a statement, Schering VP Thomas Koestler said he was “surprised...
- Blog posts 2008-08-01
- Johns Hopkins in Pharma Funding Flap
- Is Johns Hopkins University Medical School offering to endorse drug company "educational" materials for money? That was the allegation made last week by Daniel Carlat, a blogger and psychiatrist in private practice. Johns Hopkins, naturally, denies the claim. Carlat says Johns Hopkins is offering...
- Blog posts 2008-08-05
- GSK Roiled by Layoffs: 350 R&D Staff Cut; Scientists in Italy Stage a Strike
- Confusion continues at GlaxoSmithKline this morning as R&D employees attempt to figure out if they'll be receiving pink slips and their bosses attempt to keep everyone calm. Tension at the company has been building since Chemistry World reported that GSK sought hundreds of job cuts internationally at...
- Blog posts 2008-08-05
- Is Pfizer's Sleeping Pill Obsession Running up King Stock?
- Trading in options on King Pharmaceuticals shares reached a four-year frenzy yesterday, Reuters reported, and King shares rose to an 11-month high on rumors that Pfizer may be interested in acquiring it. Pfizer pfollowers know that CEO Jeff Kindler made a lot of noise a few years...
- Blog posts 2008-08-06
- As "Superbugs" Rise, Companies Abandon Antibiotic Research
- This week's must-read is Jerome Groopman's article on super-resistant bacteria in the New Yorker. If you get infected, the bacteria destroy your lungs and you end up drowning in your own blood. There's no cure: Antibiotics no longer work against them. These bugs are "literally resistant to...
- Blog posts 2008-08-07
- GSK and Others See Massachusetts Showdown Over Drug-Marketing Reform
- There are two ideas floating in the world of politics to curb the way drug companies give doctors gifts and often biased information. One of them is a good idea, and one of them is a bad idea. Drug companies -- such as GlaxoSmithKline -- have chosen...
- Blog posts 2008-08-08
- GSK's Alli Diet Drug Has Problems With Your "Fat Friend"
- The official blog of GlaxoSmithKline's Alli diet drug franchise has suddenly adopted a decidedly different voice. Alliconnect used to be a series of posts about health, nutrition, and some upfront warnings about Alli's side effects eat too much fatty food and you can lose bowel control. It...
- Blog posts 2008-08-11
- It’s Good News, Bad News for Gilead’s HIV Pill
- The good news: The FDA approved Viread, Gilead’s dwindling HIV treatment, as a therapy for hepatitis B. The drug’s sales had gone down to $613 million from a peak of $783 million as newer combination drugs -- including Gilead’s own Atripla, which includes Viread -- eroded the market for standalone...
- Blog posts 2008-08-12
- GSK Employees Really Love Their Boss's Book -- It's "Better Than Harvard"!
- Stephen Stefano, one of GlaxoSmithKline's senior executives in charge of commercial strategy, has written a book about leadership. It's called Passion and ICE. And, according to the employees and business partners of the senior-vice-president-of-managed-markets-and-neurohealth-divisions-turned-motivational speaker, Steve's book is totally awesome! Here's a selection of the completely unbiased,...
- Blog posts 2008-08-13
- At Sepracor, a Cost-Cutting Exercise Proves Expensive
- Last year, Sepracor, the maker of sleeping pill Lunesta, announced it would reduce its sales and marketing expenses by $90-100 million in 2008, "including an anticipated reduction of approximately 300 sales force positions." The company said it needed to make the layoffs because, by last October, its revenues were falling....
- Blog posts 2008-08-13
- Not Everyone Thinks Pharma's Legal Liabilities Are Impossible to Calculate
- Few things are less sexy than proposed changes in accounting rules for drug companies, but bear with me -- this is actually interesting. Lilly, Johnson & Johnson, Merck, Novartis, Pfizer and Wyeth have complained about a rule change that would require them to estimate how large their...
- Blog posts 2008-08-14
- << Previous
- page 1 of 52
- Next >>
Refining Tags
- Marketing (238 results)
- Finance (218 results)
- Advertisement (210 results)
- Human Resources (170 results)
- Business Operations (126 results)
- Sales (124 results)
- Government (121 results)
- Advertising & Promotion (118 results)
- Sales Strategy (115 results)
- Federal Government (104 results)
- Agency (103 results)
- Pfizer Inc. (101 results)
- Investment (92 results)
- Workforce Management (79 results)
- Operational Accounting (79 results)
- Sales Force Management (76 results)
- FDA (75 results)
- Layoff (65 results)
- Benefits (63 results)
- Revenue (58 results)
- Corporate Law (54 results)
- Financial Accounting (48 results)
- CEO (46 results)
- Internet (45 results)
- Healthcare (44 results)
- Mergers & Acquisitions (41 results)
- Marketing Research (41 results)
- Branding (38 results)
- Corporate Communications (38 results)
- Corporate Governance (35 results)
- Johnson & Johnson (35 results)
- Management (34 results)
- Merck & Co. Inc. (34 results)
- Pharmaceutical Company (31 results)
- Litigation (31 results)
- Bayer AG (31 results)
- WPP (31 results)
- Software (30 results)
- Gender And Diversity (30 results)
- Enterprise Software (30 results)
- Stock (29 results)
- Wyeth (29 results)
- Job (28 results)
- Personal Finance (28 results)
- Recruitment & Selection (28 results)
- Vertical Industries (27 results)
- AstraZeneca Plc. (26 results)
- Patient (26 results)
- GSK (26 results)
- Financial Planning (25 results)
